Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/17/2025 | $6.00 | Sell | Citigroup |
2/28/2025 | $19.00 | Buy | BTIG Research |
7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan |
5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities |
5/10/2024 | Underweight → Neutral | JP Morgan | |
8/9/2023 | $15.00 | Neutral → Buy | B. Riley Securities |
4/20/2023 | $55.00 → $10.00 | Outperform → Market Perform | TD Cowen |
3/1/2023 | $29.00 → $10.00 | Buy → Neutral | B. Riley Securities |
Citigroup initiated coverage of Novavax with a rating of Sell and set a new price target of $6.00
BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00
JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00
8-K - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
144 - NOVAVAX INC (0001000694) (Subject)
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO